Internet Sales of "Research Grade Compounds": The Opioid SR-17018 (SR-17) as an Example
{"Several":[0],"internet":[1],"sites":[2],"promote":[3],"the":[4,10,24,44,66,94,102,110,125,128,152,191],"sale":[5],"of":[6,19,79,98,105,124,154,169,190,209],"\\"research":[7,138,196],"grade":[8,139,197],"compounds.\\"Although":[9],"purchaser":[11],"attests":[12],"that":[13,23,35,136,194],"they":[14,21,36],"are":[15,46,144],"over":[16],"18":[17],"years":[18],"age,":[20],"know":[22],"substances":[25],"have":[26],"not":[27,38],"been":[28],"approved":[29],"by":[30],"regulatory":[31],"agencies":[32],"and":[33,205,211],"promise":[34],"will":[37],"use":[39,56],"them":[40],"for":[41,54,60,113,161],"human":[42,61,114,156,207],"consumption,":[43],"compounds":[45],"supplied":[47],"in":[48,201],"tablet":[49],"form,":[50],"which":[51,179],"is":[52,65],"inconvenient":[53],"research":[55,121],"but":[57],"very":[58],"convenient":[59],"consumption.One":[62],"such":[63,141,170],"compound":[64,172],"opioid":[67,96],"SR-17018":[68,143,185],"(aka":[69],"\\"SR-17\\").SR-17018":[70],"was":[71],"originally":[72],"synthesized":[73],"at":[74],"Scripps":[75],"Research":[76],"as":[77,142,146,186],"part":[78],"a":[80,86,120,159,171,187,195,220],"discovery":[81],"effort":[82],"to":[83,180],"test":[84],"whether":[85],"G-protein-'biased'":[87],"mu-opioid":[88],"receptor":[89],"(MOR)":[90],"agonist":[91],"could":[92],"separate":[93],"undesirable":[95],"effect":[97,104],"respiratory":[99],"depression":[100],"from":[101],"desirable":[103],"analgesia.It":[106],"never":[107],"progressed":[108],"through":[109],"stages":[111],"necessary":[112],"clinical":[115,192],"trials,":[116],"so":[117],"it":[118,212],"remained":[119],"\\"tool\\"":[122],"drug.Regardless":[123],"initial":[126],"intent,":[127],"United":[129],"States":[130],"Drug":[131],"Enforcement":[132],"Agency":[133],"(DEA)":[134],"alerts":[135],"some":[137],"compounds\\"":[140],"emerging":[145],"recreational":[147],"or":[148],"abused":[149],"substances.If":[150],"so,":[151],"absence":[153],"adequate":[155,175],"data":[157],"creates":[158],"problem":[160],"healthcare":[162],"providers":[163],"who":[164],"may":[165],"encounter":[166],"an":[167,174,214],"overdose":[168],"without":[173],"evidence":[176],"base":[177],"upon":[178],"draw.This":[181],"narrative":[182],"review":[183],"presents":[184,213],"case":[188],"study":[189],"uncertainty":[193],"compound\\"":[198],"introduces.It":[199],"synthesizes":[200],"vitro,":[202],"ex":[203],"vivo,":[204],"plausible":[206],"pharmacology":[208],"SR-17018,":[210],"emergency":[215],"department":[216],"physician's":[217],"experience":[218],"with":[219],"suspected":[221],"SR-17":[222],"overdose.":[223]}
Authors
- Joseph V. Pergolizzi (ORCID: https://orcid.org/0000-0001-5658-1471)
- Eugene Vortsman
- Robert B Raffa
Institutions
- Northwell Health (US)
- North Shore Diabetes and Endocrine Associates (US)
- Nema Research (United States) (US)
- Temple University (US)
Publication Details
- Journal
- Cureus
- Published
- 2026-09-16
- DOI
- https://doi.org/10.7759/cureus.116383
- Primary Topic
- Eicosanoids and Hypertension Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00